Published in Curr Protoc Immunol on November 01, 2001
T cell surveillance of oncogene-induced prostate cancer is impeded by T cell-derived TGF-β1 cytokine. Immunity (2011) 1.85
Gene signatures distinguish stage-specific prostate cancer stem cells isolated from transgenic adenocarcinoma of the mouse prostate lesions and predict the malignancy of human tumors. Stem Cells Transl Med (2013) 1.50
A systems genetics approach identifies CXCL14, ITGAX, and LPCAT2 as novel aggressive prostate cancer susceptibility genes. PLoS Genet (2014) 1.48
Combination therapy with a second-generation androgen receptor antagonist and a metastasis vaccine improves survival in a spontaneous prostate cancer model. Clin Cancer Res (2013) 1.15
Mechanisms of apoptosis by the tumor suppressor Par-4. J Cell Physiol (2012) 1.13
Sox9 is required for prostate development and prostate cancer initiation. Oncotarget (2012) 1.09
A novel patient-derived intra-femoral xenograft model of bone metastatic prostate cancer that recapitulates mixed osteolytic and osteoblastic lesions. J Transl Med (2011) 1.00
Simian virus 40 transformation, malignant mesothelioma and brain tumors. Expert Rev Respir Med (2011) 0.96
Retinoid metabolism and ALDH1A2 (RALDH2) expression are altered in the transgenic adenocarcinoma mouse prostate model. Biochem Pharmacol (2009) 0.96
Apoptosis and tumor resistance conferred by Par-4. Cancer Biol Ther (2008) 0.95
LL-37 as a therapeutic target for late stage prostate cancer. Prostate (2010) 0.95
Analyses of the role of endogenous SPARC in mouse models of prostate and breast cancer. Clin Exp Metastasis (2007) 0.94
Macrophage inhibitory cytokine-1 (MIC-1/GDF15) slows cancer development but increases metastases in TRAMP prostate cancer prone mice. PLoS One (2012) 0.93
A review of the existing grading schemes and a proposal for a modified grading scheme for prostatic lesions in TRAMP mice. Toxicol Pathol (2011) 0.90
Retracted Isolation of immune cells from primary tumors. J Vis Exp (2012) 0.90
Plumbagin inhibits prostate cancer development in TRAMP mice via targeting PKCε, Stat3 and neuroendocrine markers. Carcinogenesis (2012) 0.88
Ipilimumab and cancer immunotherapy: a new hope for advanced stage melanoma. Yale J Biol Med (2011) 0.88
Lineage relationship of prostate cancer cell types based on gene expression. BMC Med Genomics (2011) 0.87
Opposing roles of Dnmt1 in early- and late-stage murine prostate cancer. Mol Cell Biol (2010) 0.87
ER stress drives Lipocalin 2 upregulation in prostate cancer cells in an NF-κB-dependent manner. BMC Cancer (2011) 0.85
Germline genetic variation modulates tumor progression and metastasis in a mouse model of neuroendocrine prostate carcinoma. PLoS One (2013) 0.83
GPR56 plays varying roles in endogenous cancer progression. Clin Exp Metastasis (2010) 0.83
The steroid receptor coactivator-3 is required for developing neuroendocrine tumor in the mouse prostate. Int J Biol Sci (2014) 0.82
Genetic ablation of metadherin inhibits autochthonous prostate cancer progression and metastasis. Cancer Res (2014) 0.81
TRAMP prostate tumor growth is slowed by walnut diets through altered IGF-1 levels, energy pathways, and cholesterol metabolism. J Med Food (2014) 0.80
GNL3 and SKA3 are novel prostate cancer metastasis susceptibility genes. Clin Exp Metastasis (2015) 0.79
Targeted BikDD expression kills androgen-dependent and castration-resistant prostate cancer cells. Mol Cancer Ther (2014) 0.79
Pomegranate Extracts in the Management of Men's Urologic Health: Scientific Rationale and Preclinical and Clinical Data. Evid Based Complement Alternat Med (2013) 0.78
Restoration of tumor suppression in prostate cancer by targeting the E3 ligase E6AP. Oncogene (2016) 0.77
How do I steer this thing? Using dendritic cell targeted vaccination to more effectively guide the antitumor immune response with combination immunotherapy. J Immunother Cancer (2016) 0.77
GRK3 is a direct target of CREB activation and regulates neuroendocrine differentiation of prostate cancer cells. Oncotarget (2016) 0.77
Apigenin suppresses migration and invasion of transformed cells through down-regulation of C-X-C chemokine receptor 4 expression. Toxicol Appl Pharmacol (2013) 0.77
5α-reductase 1 mRNA levels are positively correlated with TRAMP mouse prostate most severe lesion scores. PLoS One (2017) 0.76
Dissection of Individual Prostate Lobes in Mouse Models of Prostate Cancer to Obtain High Quality RNA. J Cell Physiol (2016) 0.76
Mapping Complex Traits in a Diversity Outbred F1 Mouse Population Identifies Germline Modifiers of Metastasis in Human Prostate Cancer. Cell Syst (2016) 0.76
PSMA redirects cell survival signaling from the MAPK to the PI3K-AKT pathways to promote the progression of prostate cancer. Sci Signal (2017) 0.75
Repertoire enhancement with adoptively transferred female lymphocytes controls the growth of pre-implanted murine prostate cancer. PLoS One (2012) 0.75
Estrogen receptors in prostate development and cancer. Am J Clin Exp Urol (2014) 0.75
Development of High Resolution 3D Hyperpolarized Carbon-13 MR Molecular Imaging Techniques. Magn Reson Imaging (2017) 0.75
Copper as a target for prostate cancer therapeutics: copper-ionophore pharmacology and altering systemic copper distribution. Oncotarget (2016) 0.75
Leucine-rich repeat-containing G protein coupled receptor 4 (Lgr4) is necessary for prostate cancer metastasis via epithelial-mesenchymal transition. J Biol Chem (2017) 0.75
Enhancement of antitumor immunity by CTLA-4 blockade. Science (1996) 17.94
CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med (1995) 8.31
CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones. Nature (1992) 7.15
CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells. J Exp Med (1996) 6.13
Tumor-specific antigen of murine T-lymphoma defined with monoclonal antibody. J Immunol (1982) 5.92
The emerging role of CTLA-4 as an immune attenuator. Immunity (1997) 5.35
ICOS co-stimulatory receptor is essential for T-cell activation and function. Nature (2001) 5.32
Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells. Science (1993) 5.30
CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy. Annu Rev Immunol (2001) 5.17
Metastatic prostate cancer in a transgenic mouse. Cancer Res (1996) 4.02
Limited diversity of gamma delta antigen receptor genes of Thy-1+ dendritic epidermal cells. Cell (1988) 3.88
Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) regulates the unfolding of autoimmune diabetes. J Exp Med (1998) 3.70
Characterization of prostatic epithelial cell lines derived from transgenic adenocarcinoma of the mouse prostate (TRAMP) model. Cancer Res (1997) 3.67
CTLA-4-Mediated inhibition of early events of T cell proliferation. J Immunol (1999) 3.49
Developmentally ordered appearance of thymocytes expressing different T-cell antigen receptors. Nature (1988) 3.48
Clinical significance of defective dendritic cell differentiation in cancer. Clin Cancer Res (2000) 3.47
Identification and distribution of the costimulatory receptor CD28 in the mouse. J Immunol (1992) 3.37
T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer. Proc Natl Acad Sci U S A (2001) 3.15
Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade. Cancer Res (2000) 2.89
CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma. Proc Natl Acad Sci U S A (1998) 2.78
Lymphoproliferation in CTLA-4-deficient mice is mediated by costimulation-dependent activation of CD4+ T cells. Immunity (1997) 2.72
Costimulatory regulation of T cell function. Curr Opin Cell Biol (1999) 2.69
Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer. Proc Natl Acad Sci U S A (1997) 2.53
The T cell antigen receptor complex expressed on normal peripheral blood CD4-, CD8- T lymphocytes. A CD3-associated disulfide-linked gamma chain heterodimer. J Exp Med (1987) 2.52
Recognition of self antigens by skin-derived T cells with invariant gamma delta antigen receptors. Science (1991) 2.49
Expression and function of the CD3-antigen receptor on murine CD4+8+ thymocytes. Nature (1987) 2.38
Pathologic progression of autochthonous prostate cancer in the TRAMP model. Prostate Cancer Prostatic Dis (1999) 2.37
Co-stimulation in T cell responses. Curr Opin Immunol (1997) 2.35
Refined structure of alkaline phosphatase from Escherichia coli at 2.8 A resolution. J Mol Biol (1985) 2.31
Regulation of gene expression by hypertonicity. Annu Rev Physiol (1997) 2.21
The role of CTLA-4 in the regulation and initiation of T-cell responses. Immunol Rev (1996) 2.18
Structure, function, and serology of the T-cell antigen receptor complex. Annu Rev Immunol (1987) 2.17
Androgen-independent prostate cancer progression in the TRAMP model. Cancer Res (1997) 2.16
The mouse T cell receptor: structural heterogeneity of molecules of normal T cells defined by xenoantiserum. Cell (1983) 2.04
Regulation of T-cell receptor gamma-chain RNA expression in murine Thy-1+ dendritic epidermal cells. Nature (1987) 2.00
CD28-B7 interactions allow the induction of CD8+ cytotoxic T lymphocytes in the absence of exogenous help. J Exp Med (1993) 1.93
A transgenic mouse prostate cancer model. Toxicol Pathol (1997) 1.91
Identification of antigen receptor-associated structures on murine T cells. Nature (1985) 1.79
Targeted expression of des(1-3) human insulin-like growth factor I in transgenic mice influences mammary gland development and IGF-binding protein expression. Endocrinology (1996) 1.74
The murine homologue of the T lymphocyte antigen CD28. Molecular cloning and cell surface expression. J Immunol (1990) 1.74
Origin of Thy-1+ dendritic epidermal cells of adult mice from fetal thymic precursors. Nature (1990) 1.73
Distinct antigen receptor repertoires of two classes of murine epithelium-associated T cells. Nature (1989) 1.73
Murine Ia and human DR antigens: homology of amino-terminal sequences. Proc Natl Acad Sci U S A (1978) 1.70
Cytotoxic T lymphocyte antigen-4 (CTLA-4) regulates primary and secondary peptide-specific CD4(+) T cell responses. Proc Natl Acad Sci U S A (1999) 1.70
Superantigen responses and co-stimulation: CD28 and CTLA-4 have opposing effects on T cell expansion in vitro and in vivo. Int Immunol (1996) 1.69
Thymocyte development is normal in CTLA-4-deficient mice. Proc Natl Acad Sci U S A (1997) 1.67
Angiogenesis and prostate cancer: identification of a molecular progression switch. Cancer Res (2001) 1.66
Elimination of residual metastatic prostate cancer after surgery and adjunctive cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) blockade immunotherapy. Proc Natl Acad Sci U S A (1999) 1.61
Genistein in the diet reduces the incidence of poorly differentiated prostatic adenocarcinoma in transgenic mice (TRAMP). Cancer Res (2001) 1.59
Limited diversity of T-cell receptor gamma-chain expression of murine Thy-1+ dendritic epidermal cells revealed by V gamma 3-specific monoclonal antibody. Proc Natl Acad Sci U S A (1989) 1.49
In vivo blockade of CTLA-4 enhances the priming of responsive T cells but fails to prevent the induction of tumor antigen-specific tolerance. Proc Natl Acad Sci U S A (1999) 1.48
Secondary but not primary T cell responses are enhanced in CTLA-4-deficient CD8+ T cells. Eur J Immunol (1998) 1.45
Normal and abnormal development of the male urogenital tract. Role of androgens, mesenchymal-epithelial interactions, and growth factors. J Androl (1993) 1.44
The insulin-like growth factor axis and prostate cancer: lessons from the transgenic adenocarcinoma of mouse prostate (TRAMP) model. Cancer Res (1999) 1.42
Delta is the Cx-gene product in the gamma/delta antigen receptor of dendritic epidermal cells. Nature (1988) 1.41
Osmotic regulation of gene expression. FASEB J (1996) 1.40
Two signals are required for negative selection of CD4+CD8+ thymocytes. J Immunol (1993) 1.39
Interaction of CTLA-4 with AP50, a clathrin-coated pit adaptor protein. Proc Natl Acad Sci U S A (1997) 1.36
Defensins are mitogenic for epithelial cells and fibroblasts. J Cell Physiol (1993) 1.35
Mutations at the boundary of the hinge and ligand binding domain of the androgen receptor confer increased transactivation function. Mol Endocrinol (2001) 1.35
Correlation of cell surface antigen expression on human thymocytes by multi-color flow cytometric analysis: implications for differentiation. J Immunol (1986) 1.33
Monoclonal antibodies recognizing oval cells induced in the liver of rats by N-2-fluorenylacetamide or ethionine in a choline-deficient diet. Cancer Res (1985) 1.32
Pinpointing when T cell costimulatory receptor CTLA-4 must be engaged to dampen diabetogenic T cells. Proc Natl Acad Sci U S A (2000) 1.31
E-7869 (R-flurbiprofen) inhibits progression of prostate cancer in the TRAMP mouse. Cancer Res (2000) 1.31
Human DR (Ia-like) antigens: biological and molecular profile. Contemp Top Mol Immunol (1978) 1.31
Activation and differentiation requirements of primary T cells in vitro. Proc Natl Acad Sci U S A (1993) 1.29
Cancer immunotherapy: co-stimulatory agonists and co-inhibitory antagonists. Clin Exp Immunol (2009) 1.28
Phenotypic analysis and gamma delta-T cell receptor repertoire of murine T cells associated with the vaginal epithelium. J Immunol (1991) 1.28
A role for phospholipase C-gamma-mediated signaling in tumor cell invasion. Clin Cancer Res (1999) 1.25
Specific blockade of CTLA-4/B7 interactions results in exacerbated clinical and histologic disease in an actively-induced model of experimental allergic encephalomyelitis. J Neuroimmunol (1997) 1.24
Chemoprevention of prostate carcinogenesis by alpha-difluoromethylornithine in TRAMP mice. Cancer Res (2000) 1.24
CD28-mediated costimulation is necessary for optimal proliferation of murine NK cells. J Immunol (1994) 1.18
Collocation of androgen receptor gene mutations in prostate cancer. Clin Cancer Res (2001) 1.17
Autochthonous mouse models for prostate cancer: past, present and future. Semin Cancer Biol (2001) 1.16
A subset of T cell receptors associated with L3T4 molecules mediates C6VL leukemia cell binding of its cognate retrovirus. Cell (1987) 1.15
Structure and transcription analysis of the gene encoding a cellobiase from Agrobacterium sp. strain ATCC 21400. J Bacteriol (1988) 1.15
Epithelial development in the rat ventral prostate, anterior prostate and seminal vesicle. Acta Anat (Basel) (1996) 1.14
Regulation, initiation, and termination of the cenA and cex transcripts of Cellulomonas fimi. J Bacteriol (1987) 1.14
Conditional activation of FGFR1 in the prostate epithelium induces angiogenesis with concomitant differential regulation of Ang-1 and Ang-2. Oncogene (2007) 1.13
Down-regulation of prostasin serine protease: a potential invasion suppressor in prostate cancer. Prostate (2001) 1.13
Cytotoxic T lymphocyte antigen-4 (CTLA-4) regulates the size, reactivity, and function of a primed pool of CD4+ T cells. Proc Natl Acad Sci U S A (2000) 1.13
Distinct epitopes on the T cell antigen receptor of HPB-ALL tumor cells identified by monoclonal antibodies. J Immunol (1986) 1.12
Identification of dipeptidyl peptidase IV as a protein shared by the plasma membrane of hepatocytes and liver biomatrix. Exp Cell Res (1985) 1.09
Smooth muscle-epithelial interactions in normal and neoplastic prostatic development. Acta Anat (Basel) (1996) 1.09
Specificity and longevity of antitumor immune responses induced by B7-transfected tumors. Cancer Res (1994) 1.08
T-cell activation: integration of signals from the antigen receptor and costimulatory molecules. Immunol Today (1995) 1.07